Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Piroxicam in transitional cell carcinoma of the canine bladder
Transitional cell carcinomas of the urinary bladder sometimes occur especially in older dogs. Often they are nonresecatable. Is piroxicam, a nonsteroidal antiinflammatory drug, a therapy that can be recommended?

Thirty-four dogs with histopathologically confirmed, measurable, nonresectable transitional cell carcinoma of the urinary bladder were treated with piroxicam (0.3 mg/kg PO sid) and were evaluated for tumor response and drug toxicity.

Dogs were evaluated at the Purdue University Veterinary Teaching Hospital by means of physical examination, thoracic and abdominal radiography, cystography, complete blood count, serum biochemistry profile, and urinalysis.
In selected cases, prostaglandin E2 (PGE2) concentrations in plasma and in supernatants of stimulated monocytes, and natural killer cell activity were quantified.

Dogs were evaluated before therapy and at 28 and 56 days after initiation of therapy. Dogs with stable disease or remission at 56 days remained on the study and were evaluated at 1 to 2 months intervals.

Tumor responses were 2 complete remissions, 4 partial remissions, 18 stable diseases, and 10 progressive diseases.

The median survival of all dogs was 181 days (range, 28 to 720+ days), with 2 dogs still alive.

Piroxicam toxicity consisted of gastrointestinal irritation in 6 dogs and renal papillary necrosis (detected at necropsy) in 2 dogs.

Monocyte production of PGE2 appeared to decrease with therapy in dogs whose tumors were decreasing in size, and increased in dogs with tumor progression.

A consistent pattern in natural killer cell activity was not observed. In vitro cytotoxicity assays against 4 canine tumor cell lines revealed no direct antitumor effects of piroxicam.

In summary, antitumor activity, which was not likely the result of a direct cytotoxic effect, was observed in dogs with transitional cell carcinoma of the bladder treated with piroxicam.

Source: Knapp DW, et al (1995): Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. In: J Vet Intern Med. 1995 Mar-Apr;9(2):113-4.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Patient-specific facemask to facilitate brain biopsymembers
The objective of this pilot study was to describe the application and first preliminary data of a novel MRI and CT compatible patient-specific facemask for stereotactic brain biopsy of intracranial lesions in dogs. Five client-owned dogs presenting for neurological deficits consistent with forebrain disease were included in the study. All dogs had MRI findings consistent with an intracranial lesion. But biopsies in this region are not easy to obtain. Does an individual face mask help?

  • RET-He to diagnose iron-deficient erythropoiesis in dogsmembers
  • Hypertriglyceridemia-Associated Proteinuria in Miniature Schnauzersmembers
  • Gastrointestinal dysmotility disorders in critically ill animalsmembers
  • Disorder of sex development in a cat with chromosome mosaicism members
  • Generalized discoid lupus erythematosus in dogs members
  • Epidermolysis bullosa acquisita in dogsmembers
  • Chiari-Like Malformation and Syringomyelia in American Brussels Griffon Dogsmembers
  • Efficacy and Potential Complications of Transjugular Liver Biopsymembers
  • Hypomagnesemia in Brachycephalic Dogsmembers
  • Comparison of two minimally invasive techniques for liver biopsy members
  • Topical aqueous sirolimus and the tear production members
  • JAK 1/2 inhibitor in the treatment of canine B-cell lymphomamembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved